BDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Becton Dickinson and Co (BDX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown positive financial growth in the latest quarter and has a favorable valuation compared to its peers, the technical indicators are bearish, and there are no strong positive trading signals or recent news catalysts to support immediate entry. The stock may be worth monitoring for a better entry point.
The MACD is positive and expanding, suggesting some bullish momentum. However, RSI is neutral at 39.252, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels (R1: 162.025), indicating limited upward momentum in the short term.
Hedge funds are significantly increasing their positions in BDX, with a 956.90% increase in buying over the last quarter.
The company has completed its transition to a pure-play MedTech company, which could drive long-term growth.
Financial performance in Q1 2026 shows strong YoY growth in revenue (+1.63%), net income (+26.07%), EPS (+28.85%), and gross margin (+5.13%).
Analysts have recently lowered price targets, with some expressing concerns about the company's growth recovery and flat organic growth.
The technical indicators are bearish, and the stock is trading below key resistance levels.
No recent news or event-driven catalysts to support immediate upward momentum.
In Q1 2026, BDX reported revenue of $5.25 billion (+1.63% YoY), net income of $382 million (+26.07% YoY), EPS of $1.34 (+28.85% YoY), and gross margin of 45.91% (+5.13% YoY). These figures indicate solid financial growth and operational efficiency.
Analysts are mixed on BDX. Recent ratings include several Buy ratings with price targets ranging from $170 to $233, but some analysts have lowered their targets, citing concerns about growth recovery and flat organic growth. The stock trades at an 11.5x forward earnings multiple, which is below the MedTech sector average of 20.4x, suggesting a favorable valuation.
